Administration of progesterone on the day of oocyte retrieval to reverse accumulation of fluid in the endometrial cavity during assisted reproductive techniques

Mario Cavagna1,2,3, Claudia G. Petersen1,2, Ana L. Mauri1,2, João Batista A. Oliveira1,2, Ricardo R.L. Baruffi1,2, José G. Franco Jr.1,2

1Center for Human Reproduction Prof. Franco Jr, Ribeirão Preto, SP, Brazil
2Paulista Center for Diagnosis Research and Training, Ribeirão Preto, SP, Brazil
3Women’s Health Reference Centre, Perola Byington Hospital, Sao Paulo, SP, Brazil.

ABSTRACT

Objective: To determine whether administration of progesterone on the day of oocyte retrieval may reverse accumulation of fluid in the endometrial cavity.

Methods: A total of 50 patients who underwent assisted reproductive technology (ART) cycles with endometrial cavity fluid (ECF) observed by ultrasound at the time of oocyte retrieval were included. Upon the identification of ECF, vaginal administration of natural progesterone was started. Two days later, the endometrial cavity was re-evaluated, and embryo transfer was performed in the absence of ECF.

Results: ECF was absent two days after administration of vaginal progesterone in 47 of the 50 patients (94%). ECF persisted in 3 of the 50 patients (6%). The clinical pregnancy rate per transfer was 34.0%, and the implantation rate was 21.6%.

Conclusion: Our data suggest that, in the presence of ECF, administration of intravaginal progesterone in ART cycles must be initiated on the day of follicle aspiration to reverse ECF and to avoid the deleterious effects of fluid on the blastocyst-endometrial interaction.

Keywords: Endometrial cavity fluid, progesterone, pregnancy rate, implantation rate, ART.

INTRODUCTION

The main factors responsible for a successful embryonic implantation are the embryo quality and endometrial receptivity. An adequate interaction and synchrony between the endometrium and the blastocyst are required for the implantation process (Cavagna et al., 2006; Edgell et al., 2013). Given that, it is important to perform embryo transfer in assisted reproductive technique (ART) cycles in the presence of optimal conditions of endometrial receptivity. One of the possible mechanisms of impaired endometrial receptivity is the presence of endometrial cavity fluid (ECF) on the day of embryo transfer (Sharara & McClamrock, 1997; Sharara & Prough, 1998; Levi et al., 2001). Although accumulation of fluid within the endometrial cavity is uncommon during ART, it is detrimental to embryonic implantation and negatively affects outcomes, as embryonic apposition is impaired if a fluid layer is overlaying the endometrium. The incidence of ECF in ART cycles is approximately 3%, and the outcome is particularly negative when the ECF is >3.5 mm in antero-posterior diameter (He et al., 2010). Tubal infertility, polycystic ovary syndrome (PCOS), poor ovarian response, subclinical uterine infections and physiological production in the genital tract are associated with the presence of ECF (Levi et al., 2001; Griffiths et al., 2002). Akman et al. (2005) have shown that it is more common to see fluid accumulation inside the endometrium in ART cycles of PCOS patients than tubal factor patients (22.3% versus 11.1%). However, the exact mechanism of ECF generation remains unclear, and optimal treatments for ECF have not been determined. The aim of this investigation is to determine whether therapeutic doses of natural vaginal progesterone, beginning on the day of oocyte retrieval, can reverse accumulation of fluid in the endometrial cavity and provide satisfactory clinical pregnancy rates.

MATERIAL AND METHODS

A prospective cohort study was conducted from March 2011 to November 2013 at the Center for Human Reproduction Prof. Franco Jr., Ribeirão Preto, Brazil. A total of 50 patients who underwent ART cycles with ECF observed by ultrasound at the time of oocyte retrieval (Fig 1) were included (4.9% of the total of IVF/ICSI cycles in this period). The mean fluid accumulation in the uterine cavity detected by transvaginal ultrasound in a sagittal view (A-P diameter) was 3.0±1.8 mm (2-7.8). The epidemiological data for the patients are presented in Table 1 (age, diagnosis, number of total and mature oocytes, etc.) In all cases, ovarian stimulation was performed with recombinant FSH (150-300 IU daily) and recombinant LH (75-150 IU daily). Pituitary suppression was carried out either with agonists (long protocol: 66%) or antagonists (multi doses: 34%) of GnRH. All patients were given 250 μg recombinant hCG for triggering ovulation, and oocyte retrieval was carried out 36 hours later. Upon the identification of ECF, vaginal administration of natural progesterone at a total dose of 180 mg/day (Crinone® 8%) - Serono – Brazil, twice daily - 90 mg of natural progesterone in each vaginal application) was started (Day 0). Two days later (Day 2), the endometrial cavity was re-assessed. It should be stressed that progesterone is started...
routinely in our Clinic only on the day of embryo transfer (Baruffi et al., 2003), carried out on Day 2. If ECF was absent, embryo transfer was performed. If ECF persisted, the embryos were frozen.

RESULTS

ECF was absent two days after administration of vaginal progesterone in 47 of the 50 patients (94.0%). ECF persisted in 3 of the 50 patients (6.0%). There were no significant differences with regard to age (P=0.48), etiology (P=0.66), number of oocytes collected (P=0.63), mature oocytes (P=0.40) or embryos (P=0.60) between the groups with absence or persistence of ECF after vaginal progesterone administration.

ECF persisted after the use of progesterone for the only patient with hydrosalpinx. There were three patients with PCOS in the group without ECF and two patients with PCOS in the group in which ECF persisted after administration of progesterone. In all patients, 97 embryos were transferred (2.1 per patient) and 21 had successful implantation (implantation rate: 21.6%). The clinical pregnancy rate was 32% (16/50) per patient and 34% (16/47) per transfer. There was only one miscarriage.

DISCUSSION

Endometrial receptivity is a major issue affecting implantation rates in assisted reproductive techniques (ART). There is consensus that, in ART cycles, luteal phase support with progesterone is mandatory for the promotion of an adequate environment, which in turn improves implantation rates and permits the development of the transferred embryos. Ovarian stimulation during ART cycles, as well as the utilization of GnRH analogs and follicle aspiration, lead to an endocrine disturbance during the luteal phase, interfering with the production of progesterone (Gazvani et al., 2012). Intravaginal progesterone administration is well tolerated and was demonstrated to be even more efficient than intramuscular injection, so that it remains the preferred route of administration (Smitz et al., 1992).

Regarding the duration of the supplementation, progesterone has been used for as little as two weeks and for as long as 12 weeks of gestation (Gazvani et al., 2012). With regard of the beginning of luteal support, while most infertility centers initiate progesterone on the day of oocyte retrieval, in approximately 15% of the cycles progesterone administration is initiated on the day of embryo transfer (Vaisbuch et al., 2014).

ECF is a fluid accumulation within the endometrial cavity, which is related to poor outcomes in ART cycles (He et al., 2010). In the presence of ECF, the relevant treatment options include expectant treatment, postponing embryo transfer, and transvaginal sonographic ECF aspiration (He & Zhu, 2011). Given that ECF impairs the implantation process, cryopreservation of all embryos and subsequent transfer was considered the best approach (Nikolettos et al., 2002).

This investigation was designed to determine whether initiating progesterone supplementation on the day of oocyte retrieval could reverse accumulation of fluid within the endometrial cavity, thus allowing embryo transfer in the same ART cycle. Our results indicated that 47 of 50 patients (94.0%) were negative for ECF two days after administration of intravaginal progesterone. The procedure effectively reduced the ECF visualized by ultrasound, and as such should be recommended as the main option for management of ECF in ART cycles. The mechanism by

| Characteristic | Total | Absence of ECF | Persistence of ECF | P |
|---------------|-------|----------------|-------------------|---|
| Patients      | 50    | 47             | 3                 |   |
| Cycles        | 50    | 47             | 3                 |   |
| Age (years)   |       | 33.9±4.8       | 34.1±4.6          | 30.0±8.1 | 0.48 |
|               |       | (21-43)        | (21-43)           | (23-39) |   |
| BMI           |       | 23.9±3.7       | 24.0±3.8          | 22.0±0.2 | 0.45 |
| Etiology      |       |                |                   | 0.66 |
| Idiopathic    | 30.0% (15/50) | 29.8% (14/47) | 33.3% (1/3)      |   |
| Male          | 36.0% (18/50) | 36.2% (17/47) | 33.3% (1/3)      |   |
| Endometriosis | 20.0% (10/50) | 21.3% (10/47) | 0                 |   |
| Tuboperitoneal| 10.0% (05/50) | 8.5% (04/47)  | 33.3% (1/3)      |   |
| Tuboperitoneal + endometriosis | 4.0% (02/50) | 4.2% (02/47)  | 0                 |   |
| Fluid accumulation | 3.0±1.8 mm (2-7.8) | 3.0±1.7 mm (2-7.8) | 3.0±1.3 mm (2-5.6) | 0.75 |
| Sagittal view (A-P diameter) |  |  |  |  |
| Oocytes (n) |       | 8.2±6.0        | 7.7±5.5           | 12.7±9.7 | 0.40 |
| Metaphase II |       | 11.8±7.9       | 11.2±7.5          | 16.0±12.2 | 0.63 |
| Total        | 70.8±22.5% | 71.1±23.3%    | 68.4±16.6         | 0.71 |
| Fertilization rate | 5.6±3.7 | 5.4±3.4       | 7.7±6.5           | 0.60 |
| Number of embryos | 2.1±0.6 | 2.1±0.6       | ----              |   |
| Embryo transferred (n) | 34%(16/47) | 34%(16/47)   | ----              |   |
| Pregnancy rate/transfer | 6.3%(1/16) | 6.3%(1/16)  | ----              |   |

Table I. General characteristics of the study population

ECF: endometrial cavity fluid
which progesterone may reverse ECF is not clear. Progesterone has anti-angiogenic effects and inhibits endothelial cell proliferation through a nuclear receptor-mediated mechanism (Hsu et al., 2008) and may reduce proliferation of endometrial stromal cells and suppress the transcription of VEGF (Rocha et al., 2013). These facts may exert a role in the disappearance of ECF with early administration of progesterone. Anti-inflammatory effects of progesterone, which make possible its use in neurologic situations, such as spinal cord contusions and other neurological disorders (De Nicola et al., 2013; Garcia-Ovejero et al., 2014), may also be responsible for the reduction of ECF. Moreover, progesterone regulates decidual prolactin expression, which is a marker of decidualization, and thus exerts a role in differentiating human endometrial stromal cells (Brosens et al., 1999). The effects of progesterone on differentiation of the endometrium and its anti-inflammatory and anti-angiogenic activities may explain the suppression of ECF after the treatment.

Despite recruiting all eligible participants during the study period, the sample size was small, and spontaneous remission may have occurred in some of the patients. Although spontaneous remission may have occurred, the positive results (i.e., absence of ECF in 94.0% of patients) in this observational study demonstrate that administration of vaginal progesterone beginning on the day of oocyte retrieval is an acceptable option for managing ECF in women undergoing assisted reproduction.

In conclusion, our data suggest that, in the presence of ECF, administration of intravaginal progesterone in ART cycles must be initiated on the day of follicle aspiration to reverse ECF and avoid the deleterious effects of fluid on blastocyst-endometrial interactions.

Acknowledgments: Acknowledgments The authors wish to thank the American Journal Experts for revising the English text.

CONFLICT OF INTERESTS
The authors declare that they have no conflict of interest.

Corresponding author:
Jose G. Franco Jr
Center for Human Reproduction Prof. Franco Jr
Av. Prof. João Fiusa, 689 - Ribeirao Preto/SP, Brazil
E-mail: crh@crh.com.br

REFERENCES
Akman MA, Erden HF, Bahceci M. Endometrial fluid visualized through ultrasonography during ovarian stimulation in IVF cycles impairs the outcome in tubal factor, but not PCOS patients. Hum Reprod. 2005;20:906-9.

Baruffi R, Mauri AL, Petersen CG, Felipe V, Franco JG, Jr. Effects of vaginal progesterone administration starting on the day of oocyte retrieval on pregnancy rates. J Assist Reprod Genet. 2003;20:517-20.

Brosens JJ, Hayashi N, White JO. Progesterone receptor regulates decidual prolactin expression in differentiating human endometrial stromal cells. Endocrinology.1999;140:4809-20.

Cavagna M, Pereira DM, Cavagna F, Levi-Setti PE. Receptividade endometrial: o papel das citoquinas e fatores de crescimento. JBRA Assist Reprod. 2006;10:29-33.

De Nicola AF, Coronel F, Garay LI, Gargiulo-Monachelli G, Deniselle MC, Gonzalez SL, Labombarda F, Meyer M, Guennoun R, Schumacher M. Therapeutic effects of progesterone in animal models of neurological disorders. CNS Neurol Drug Targets. 2013;12:1205-18.

Edgell TA, Rombaerts LJ, Salamonsen LA. Assessing receptivity in the endometrium: the need for a rapid, non-invasive test. Reprod Biomed Online. 2013;2:486-96.

Garcia-Ovejero D, Gonzalez S, Paniagua-Torija B, Lima A, Molina-Holgado E, De Nicola AF, Labombarda F. Progesterone reduces secondary damage, preserves white matter, and improves locomotor outcome after spinal cord contusion. J Neurotrauma. 2014;31:857-871.

Gazvani R, Russel R, Sajjad R, Alifrevic Z. Duration of luteal support (DOLS) with progesterone pessaries to improve the success rates in assisted conception: study protocol for a randomized controlled trial. Trials. 2012;13:118.

Griffiths AN, Watermeyer SR, Kientzzeris LD. Fluid within the endometrial cavity in an IVF cycle-a novel approach to its management. J Assist Reprod Genet. 2002;19:298-301.

He RH, Gao HJ, Li YQ, Zhu XM. The associated factors to endometrial cavity fluid and the relevant impact on the IVF-ET outcome. Reprod Biol Endocrinol. 2010; 8:46.

He RH, Zhu XM. How to deal with fluid in the endometrial cavity during assisted reproductive techniques. Curr Opin Obstet Gynecol. 2011;23:190-4.

Hsu SP, Ho PY, Juan SH, Liang YC, Lee WS. Progesterone inhibits human endothelial cell proliferation through a p53-dependent pathway. Cell Mol Life Sci. 2008;65:3839-50.

Levi AJ, Segars JH, Miller BT and Leondires MP. Endometrial cavity fluid is associated with poor ovarian response and increased cancellation rates in ART cycles. Hum Reprod. 2001;16:2610-5.

Nikollettos N, Asimakopoulos B, Vakalopoulos I, Simopoulos M. Endometrial fluid accumulation during controlled ovarian stimulation for ICSI treatment. A report of three cases. Clin Exp Obstet Gynecol. 2002;29:290-2.

Rocha AL, Reis FM, Taylor RN. Angiogenesis and endometriosis. Obstet Gynecol Int. 2013; 2013:859619.

Sharara FI, McLamrock HD. Endometrial fluid collection in women with hydrosalpinx after human chorionic gonadotropin administration: a report of two cases and implications for management. Hum Reprod. 1997;12: 2816-9.

Sharara FI, Prough SG. Endometrial fluid collection in women with PCOS undergoing ovarian stimulation for IVF. A report of four cases. J Reprod Med. 1998; 44:299–302.

Smitz J, Devroey P, Faguer B, Bourgain C, Camus M, Van Steirteghem AC. A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum Reprod. 1992; 7:168-75.

Vaisbuch E, de Ziegler D, Leong M, Weissman A, Shoham Z. Luteal-phase support in assisted reproduction treatment: real-life practices reported worldwide by an updated website-based survey. Reprod Biomed Online. 2014; 28:330-5.